bDMARDs Prevent ESRD in Most Patients With AA Amyloidosis bDMARDs Prevent ESRD in Most Patients With AA Amyloidosis
bDMARD therapy preserved renal function in 75% of patients with AA amyloidosis, but the remaining 25% progressed to ESRD despite receiving bDMARD therapy.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 10, 2024 Category: Allergy & Immunology Tags: Rheumatology Clinical Summary Source Type: news

Q & A: An Update on Hereditary Transthyretin Amyloidosis Q & A: An Update on Hereditary Transthyretin Amyloidosis
Morie Gertz, MD, reviews hereditary amyloidogenic transthyretin (ATTR) amyloidosis diagnosis and treatment.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 4, 2024 Category: Cancer & Oncology Tags: Neurology & Neurosurgery Commentary Source Type: news

Hereditary Amyloidosis: 5 Things to Know Hereditary Amyloidosis: 5 Things to Know
The heterogeneity of hereditary amyloidosis can delay diagnosis and seriously affect prognosis and patient quality of life; these five things are need-to-know.Medscape Oncology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 29, 2024 Category: Neurology Tags: Hematology-Oncology Commentary Source Type: news

Exercise Testing Helps Assess ATTR Exercise Testing Helps Assess ATTR
Cardiopulmonary exercise testing may be useful in characterizing distinct patterns of functional impairment in patients with transthyretin amyloidosis.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2024 Category: Cardiology Tags: Cardiology Source Type: news

Cardiac amyloidosis 101: Why early diagnosis and targeted treatment matter
Amyloidosis occurs when the body produces abnormal proteins that bind together to form a substance called amyloid. Amyloids can deposit in any tissue or organ, including the heart, kidneys, liver and nerves. When it occurs in the heart, it's called cardiac amyloidosis. Dr. Martha Grogan, a Mayo Clinic cardiologist and director of the Cardiac Amyloid Clinic at Mayo Clinic in Rochester, Minnesota, explains what cardiac amyloidosis is, why knowing the type of amyloid is key… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 21, 2024 Category: Databases & Libraries Source Type: news

Ultromics inks deal with Pfizer to develop AI technology
U.K. software developer Ultromics has entered an agreement with Pfizer to expedite marketing clearance in the U.S. for its AI algorithm for detecting cardiac amyloidosis. Under the partnership with Pfizer, Ultromics will research and pursue U.S. Food and Drug Administration (FDA) clearance for its EchoGo Amyloidosis algorithm. The software has already received Breakthrough Device designation from the FDA for the detection of cardiac amyloidosis. The algorithm uses deep learning to analyze routine ultrasound scans of the heart (echocardiograms) to detect disease that often goes undetected during standard assessments, Ultro...
Source: Headlines - January 10, 2024 Category: Radiology Authors: staff writers Tags: Industry News Ultrasound Source Type: news

FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
(MedPage Today) -- Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced on Thursday. Hereditary ATTR... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 22, 2023 Category: American Health Source Type: news

Upstate offers nuclear scan for heart issue once thought rare
Upstate's new chair of Medicine seeks to raise awareness of cardiac amyloidosis (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - December 22, 2023 Category: Universities & Medical Training Tags: News Source Type: news

FDA Approves Wainua (eplontersen) for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing Wainua demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life Additional regulatory reviews... (Source: - New Drug Approvals)
Source: - New Drug Approvals - December 21, 2023 Category: Drugs & Pharmacology Source Type: news

Colchicine: the good, the bad, the ugly, and how to minimise the risks - Stamp LK, Horsley C, Karu LT, Dalbeth N, Barclay M.
Colchicine has an important role in managing various conditions, including gout, familial Mediterranean fever, amyloidosis, Behcet's syndrome, recurrent pericarditis, and calcium pyrophosphate deposition disease. The adverse effect profile of colchicine is... (Source: SafetyLit)
Source: SafetyLit - December 3, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Diagnosing Cardiac Amyloidosis: 5 Things to Know Diagnosing Cardiac Amyloidosis: 5 Things to Know
Dr Taylor Lebeis highlights the key aspects of a diagnostic workup for cardiac amyloidosis.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 20, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Road to RSNA 2023: Molecular Imaging
This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Notably, this is the first year a scientific session is being offered that covers advances in AI in nuclear medicine. Presentations on PET imaging in prostate cancer – an approach that is witnessing widespread adoption – include an array of studies on prostate-specific membrane antigen (PSMA)-based radiotrac...
Source: Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 2023 Molecular Imaging Preview Source Type: news

Ultra-early phase scintigraphy detects ATTR cardiac amyloidosis
In this study, the researchers analyzed imaging in four patients with ATTR-CA and four patients with hypertensive cardiomyopathy (non-CA) who underwent dynamic scintigraphic scanning. They reconstructed planar images every minute from three to 20 minutes and then every five minutes from 25 to 60 minutes after injection. The H/CL ratio was assessed on each planar image. The H/CL ratio on the planar images acquired at five minutes post-injection showed a significant difference between ATTR-CA and non-CA patients, according to the findings.Ultra-early phase  Tc-99m PYP scintigraphy can detect ATTR-CA with 100% sensitivity a...
Source: Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news

Patisiran Can Preserve Functional Capacity in ATTR Amyloidosis
THURSDAY, Oct. 26, 2023 -- For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according to a study published in... (Source: - Pharma News)
Source: - Pharma News - October 26, 2023 Category: Pharmaceuticals Source Type: news

FDA Denies Approval for Patisiran in ATTR Cardiomyopathy FDA Denies Approval for Patisiran in ATTR Cardiomyopathy
In a complete response letter, the FDA said the clinical meaningfulness of patisiran ' s effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 10, 2023 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news